Literature DB >> 27040946

Antagonism of miRNA-21 Sensitizes Human Gastric Cancer Cells to Paclitaxel.

Bo Jin1, Yanping Liu2, Haijiang Wang3.   

Abstract

The development of drug resistance has largely limited the clinical outcome of anti-cancer treatment. Recent work has highlighted the involvement of non-coding RNAs, microRNAs (miRNAs), in cancer development. The present study aimed to investigate the role of miR-21 in the development of drug resistance to paclitaxel in gastric cancer cells. Our study found that the expression of miR-21 upregulated in the paclitaxel resistant cell line SGC7901/paclitaxel compared to its parental line SGC7901. Moreover, over-expression of miR-21 significantly decreased antiproliferative effects and apoptosis induced by paclitaxel, while knockdown of miR-21 dramatically increased antiproliferative effects and apoptosis induction by paclitaxel. Moreover, our results demonstrated that miR-21 may modulate the sensitivity to PTX, at least in part, by regulating the expression of P-glycoprotein.

Entities:  

Keywords:  Gastric cancer; P-glycoprotein; miRNA-21

Mesh:

Substances:

Year:  2015        PMID: 27040946     DOI: 10.1007/s12013-014-0450-2

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  11 in total

Review 1.  Molecular pathways involved in microRNA-mediated regulation of multidrug resistance.

Authors:  Rongrong Liao; Yuexia Lin; Lihui Zhu
Journal:  Mol Biol Rep       Date:  2018-09-07       Impact factor: 2.316

2.  MiR-181a, a new regulator of TGF-β signaling, can promote cell migration and proliferation in gastric cancer.

Authors:  Shaohua Ge; Haiyang Zhang; Ting Deng; Wu Sun; Tao Ning; Qian Fan; Yi Wang; Xinyi Wang; Qiumo Zhang; Zhengyang Zhou; Haiou Yang; Guoguang Ying; Yi Ba
Journal:  Invest New Drugs       Date:  2019-01-04       Impact factor: 3.850

3.  Mcl-1 stabilization confers resistance to taxol in human gastric cancer.

Authors:  Wu Shuang; Lili Hou; Yan Zhu; Qun Li; Wanglai Hu
Journal:  Oncotarget       Date:  2017-08-12

Review 4.  Current state of phenolic and terpenoidal dietary factors and natural products as non-coding RNA/microRNA modulators for improved cancer therapy and prevention.

Authors:  Bernhard Biersack
Journal:  Noncoding RNA Res       Date:  2016-07-27

Review 5.  Research Progress in microRNA-Based Therapy for Gastric Cancer.

Authors:  Xu Zhao; Gao-Feng Hu; Yan-Fen Shi; Wei Xu
Journal:  Onco Targets Ther       Date:  2019-12-24       Impact factor: 4.147

Review 6.  Mechanisms of Action And Clinical Implications of MicroRNAs in the Drug Resistance of Gastric Cancer.

Authors:  Ying Liu; Xiang Ao; Guoqiang Ji; Yuan Zhang; Wanpeng Yu; Jianxun Wang
Journal:  Front Oncol       Date:  2021-11-29       Impact factor: 6.244

7.  miR‑21‑5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3.

Authors:  Jun Chen; Chao Zhou; Junhe Li; Xiaojun Xiang; Ling Zhang; Jun Deng; Jianping Xiong
Journal:  Int J Mol Med       Date:  2018-01-18       Impact factor: 4.101

Review 8.  Non-coding RNA in drug resistance of gastric cancer.

Authors:  Ya-Jun Luo; Qing-Mei Huang; Yan Ren; Zi-Lin Liu; Cheng-Fei Xu; Hao Wang; Jiang-Wei Xiao
Journal:  World J Gastrointest Oncol       Date:  2019-11-15

Review 9.  Noncoding RNAs in gastric cancer: implications for drug resistance.

Authors:  Ling Wei; Jujie Sun; Nasha Zhang; Yan Zheng; Xingwu Wang; Liyan Lv; Jiandong Liu; Yeyang Xu; Yue Shen; Ming Yang
Journal:  Mol Cancer       Date:  2020-03-19       Impact factor: 27.401

10.  Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?

Authors:  Andrea Ritter; Marc Hirschfeld; Kai Berner; Gerta Rücker; Markus Jäger; Daniela Weiss; Markus Medl; Claudia Nöthling; Sandra Gassner; Jasmin Asberger; Thalia Erbes
Journal:  Int J Oncol       Date:  2019-11-25       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.